| 54.68 Delayed Data As of Sep 20 |  +0.86 / +1.60%Today’s Change | 30.15 Today|||52-Week Range 64.94 | +33.20% Year-to-Date |
| FDA Grants Priority Review to Global Blood's SCD Candidate Sep 06 / Zacks.com - Paid Partner Content | Why Global Blood Therapeutics Stock Jumped 10.9% Today Sep 05 / MotleyFool.com - Paid Partner Content |
| Why Is Global Blood (GBT) Up 6.2% Since Last Earnings Report? Sep 06 / Zacks.com - Paid Partner Content |
| Previous close | 53.82 |
| Today’s open | 54.30 |
| Day’s range | 53.58 - 54.86 |
| Volume | 1,282,029 |
| Average volume (3 months) | 910,635 |
| Market cap | $3.2B |
| Earnings growth (last year) | -23.39% |
| Earnings growth (this year) | -19.35% |
| Earnings growth (next 5 years) | +0.30% |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | 5.25 |
| Today’s change | Today’s % change | |
|---|---|---|
| ALKSAlkermes Plc | -0.02 | -0.09% |
| TAROTaro Pharmaceutical ... | +0.81 | +1.01% |
| MRTXMirati Therapeutics ... | +1.44 | +1.57% |
| RETAReata Pharmaceutical... | +2.57 | +2.80% |
| Next reporting date | November 6, 2019 |
| EPS forecast (this quarter) | -$1.05 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$174.2M |
| Net profit margin | -- |
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Ted W. Love |
Senior Vice President- Operations Peter Radovich |
Corporate headquarters South San Francisco, California |
